Transforming Human Insight into Breakthrough Therapies
At Apimeds, we believe the future of medicine lies in the power of actual intelligence—the clinical judgment, scientific rigor, and human empathy that drive smarter, faster, and more meaningful innovation.
Our Mission
To improve lives through the discovery, development, and delivery of therapies rooted in deep scientific insight and guided by our commitment to those who need us most—patients, physicians, and partners.
Our Lead Program: Apitox
Apitox is a novel, non-narcotic therapy derived from purified honey bee venom and developed for the treatment of inflammation and pain, including in patients with osteoarthritis. As we prepare to initiate a Phase 3 study in our lead indication, Apitox represents a new class of therapeutic innovation—natural, targeted, and scalable.
A Company Built for What’s Next
Apimeds US is publicly traded on the New York Stock Exchange (Ticker: APUS) and led by a team of experienced biopharma professionals committed to delivering meaningful healthcare advancements. We are actively pursuing licensing and acquisition opportunities to grow our pipeline and expand our impact.
Corporate Presentation
Get in Touch
Feel free to reach out by phone, email, or through our online contact form. We’re here to help and look forward to connecting with you.
Address
Apimeds US, Inc.
100 Matawan Road
Suite 325
Matawan, NJ 07747